C H Ruhlmann - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

C H Ruhlmann

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 22, 2023

MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines updateJ Herrstedt, R Clark-Snow, C H Ruhlmann, et al.

Journal of Autoimmunity|March 17, 2025

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanomaH B Tenstad, C H Ruhlmann, S Möller, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patientsF Roila, A Molassiotis, J Herrstedt, et al.

ESMO Open|March 8, 2024

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingJ Herrstedt, R Clark-Snow, C H Ruhlmann, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2026

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumoursK S Saini, M Koopman, D Martins-Branco, et al.

Pageof 1

Search research articles

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 22, 2023

MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines updateJ Herrstedt, R Clark-Snow, C H Ruhlmann, et al.

Journal of Autoimmunity|March 17, 2025

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanomaH B Tenstad, C H Ruhlmann, S Möller, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patientsF Roila, A Molassiotis, J Herrstedt, et al.

ESMO Open|March 8, 2024

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomitingJ Herrstedt, R Clark-Snow, C H Ruhlmann, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2026

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumoursK S Saini, M Koopman, D Martins-Branco, et al.

Pageof 1